RHONE-POULENC's ACQUISITION OF FRENCH NONPRESCRIPTION DRUG DISTRIBUTOR
This article was originally published in The Tan Sheet
RHONE-POULENC's ACQUISITION OF FRENCH NONPRESCRIPTION DRUG DISTRIBUTOR Cooperation Pharmaceutique Francaise (Cooper) was approved by both companies' boards of directors on Feb. 24. Cooper announced in a same-day press release that it is encouraging its shareholders to tender their shares to Rhone-Poulenc S.A. by the end of March. The offer values Cooper at between FFr 2.8 bil. and FFr 3 bil., or approximately $500 mil. (based on an exchange rate of $1 = FFr 5.84).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC